The combination of cortical lesions and central vein sign in MRI increases the specificity and sensitivity for diagnosing multiple sclerosis. This study suggests that CLs and CVS, when used together, ...

Researchers discover that the nerve cells that make us uniquely human are also uniquely vulnerable to dying during the waves ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...

New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to ...

What causes gray matter loss in Multiple Sclerosis? New research identifies DNA damage in CUX2 neurons as a primary driver of MS progression.

The patient underwent head computed tomography (CT) and magnetic resonance imaging (MRI) of the brain. These showed multiple, bilateral lesions with surrounding edema on fluid-attenuated inversion ...

Changes in NAWM and NAGM are crucial in MS progression, challenging the traditional lesion-centric model. Subtle alterations in myelin integrity, immune cell function, and neuronal connectivity ...

– New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to ...